indomethacin has been researched along with Carcinoma, Epidermoid in 73 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the mechanisms by which caffeic acid phenethyl ester (CAPE), a phenolic antioxidant, inhibited the stimulation of prostaglandin (PG) synthesis in cultured human oral epithelial cells and in an animal model of acute inflammation." | 7.70 | Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. ( Carothers, AM; Dannenberg, AJ; Grunberger, D; Koboldt, C; Masferrer, JL; Mestre, JR; Michaluart, P; Sacks, PG; Subbaramaiah, K; Tanabe, T; Zweifel, BS, 1999) |
| "We investigated the mechanisms by which caffeic acid phenethyl ester (CAPE), a phenolic antioxidant, inhibited the stimulation of prostaglandin (PG) synthesis in cultured human oral epithelial cells and in an animal model of acute inflammation." | 3.70 | Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. ( Carothers, AM; Dannenberg, AJ; Grunberger, D; Koboldt, C; Masferrer, JL; Mestre, JR; Michaluart, P; Sacks, PG; Subbaramaiah, K; Tanabe, T; Zweifel, BS, 1999) |
| " The direct cytotoxicity of piroxicam indomethacin, and aspirin against 4 canine tumor cell lines (transitional cell carcinoma, squamous cell carcinoma, melanoma, and soft tissue sarcoma) was determined in short-term growth rate assays and in clonogenic assays." | 3.69 | Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. ( Chan, TC; Knapp, DW; Kuczek, T; Park, B; Reagan, WJ, 1995) |
| "Orally administered indomethacin at 10-600 micrograms per mouse per day has been shown to inhibit UV radiation-induced erythema dose responsively." | 3.69 | The protective effect of indomethacin on photocarcinogenesis in hairless mice. ( Boehm-Wilcox, C; Bosnic, M; Matheson, MJ; Reeve, VE, 1995) |
| "Head and neck squamous cell carcinoma (HNSCC) is associated with profound defects in cellular immunity." | 2.76 | A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. ( Baltzer, L; Brandwein, HJ; Franco, JL; Freeman, SM; Hadden, JW; Kenady, DE; Roth, Z, 2011) |
| "Thirteen patients with advanced squamous cell carcinoma of the head and neck region." | 2.69 | Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. ( Barrera, JL; de la Garza, J; Hadden, JW; Meneses, A; Verastegui, E; Zinser, J, 1998) |
| "Indomethacin has been shown clinically to inhibit growth of SCCHN (Panje, 1981)." | 2.40 | Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors. ( Adams, GL; Bach, FH; Cross, DS; Juhn, SK; Platt, JL, 1997) |
| "Paclitaxel has the capacity to activate NF-κB in oral squamous carcinoma cells." | 1.37 | The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition. ( Caicedo-Granados, EE; Lee, GS; Marker, PH; Ondrey, FG; Wuertz, BR, 2011) |
| "Esophageal and tongue cancers have both been associated with dietary zinc deficiency (ZD), and cyclooxygenase (COX-2) is often overexpressed in these cancers." | 1.33 | Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. ( Farber, JL; Fong, LY; Jiang, Y; Zhang, L, 2005) |
| "In this study, we used an oral squamous cell carcinoma cell line to study growth inhibition and changes in critical cell cycle-regulating proteins induced by the selective COX-2 inhibitor celecoxib." | 1.32 | Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma. ( Chau, M; Gilbert, R; Jordan, RC; Lim, MS; Lim, S; Mäkitie, AA; Viani, MA, 2003) |
| "All 5 cell lines constantly showed growth suppression with positive dosage effect of indomethacin." | 1.31 | In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis. ( Chang, RC; Kao, SY; Tu, SF; Wu, CH; Yang, CC, 2002) |
| "In a separate group of 17 patients with squamous cell carcinoma of the head and neck, tumor cells were isolated from fresh tumor specimens, and 24-hour PGE2 production in vitro was assayed." | 1.29 | Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. ( Heo, DS; Johnson, JT; Klapan, I; Milanovich, M; Schwartz, D; Snyderman, CH; Wagner, R; Whiteside, TL, 1994) |
| "Metastatic squamous cell head and neck cancer was treated in four patients with low-dose cyclophosphamide (to reduce suppressor T-cell activity), indomethacin (to reduce prostaglandins that mediate macrophage-induced immune suppression), zinc (to augment T-cell function via thymulin), and mixed natural interleukins perilymphatically in the neck (as adjuvant for tumor antigen in the region)." | 1.29 | Interleukins and contrasuppression induce immune regression of head and neck cancer. ( Baekey, P; Endicott, J; Hadden, EM; Hadden, JW; Skipper, P, 1994) |
| "The tongue derived squamous carcinoma cell line, SCC-25, was treated with three leukotriene synthesis inhibitors and indomethacin." | 1.29 | Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. ( Adams, GL; Juhn, SK; Ondrey, FG, 1996) |
| "Human head and neck squamous cell carcinoma (HNSCC) cultures were established from cancers of two patients." | 1.29 | Prostaglandin E2-protein kinase A signaling and protein phosphatases-1 and -2A regulate human head and neck squamous cell carcinoma motility, adherence, and cytoskeletal organization. ( Djordjevic, A; Lozano, Y; Petruzzelli, GJ; Taitz, A; Young, MR, 1996) |
| "The results demonstrate that human oral squamous carcinoma cell lines produce an immunosuppressive factor that may have a role in tumour evasion of the host immune response." | 1.28 | Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. ( Crane, IJ; Prime, SS; Rice, SQ; Scully, C, 1992) |
| "Indomethacin was found to delay the onset and reduce the size of tumours in BP- but not DMBA-treated mice." | 1.28 | A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice. ( Andrews, J; Halliday, GM; Muller, HK, 1991) |
| "Several cultured human squamous cell carcinoma cell lines (SCC-4, SCC-12B2, SCC-12F2, EC-GI-10, and BEN) and one normal keratinocyte line (Epy-1) were investigated for the production of bone resorption-stimulating activity (BRSA)." | 1.28 | Squamous cell carcinomas often produce more than a single bone resorption-stimulating factor: role of interleukin-1 alpha*. ( Gaffney, EV; Goad, DL; Morrison, NE; Nowak, RA; Tashjian, AH, 1990) |
| "Treatment with etretinate and in a later phase with indomethacin and prednisolone was not effective, except for a limited initial response of the tumour to etretinate." | 1.28 | Xeroderma pigmentosum: squamous cell carcinoma of the tongue. ( Keukens, F; Kleijer, WJ; Oosterhuis, JW; Panders, AK; van Voorst Vader, PC; Vinks, S, 1989) |
| "When 12 patients with basal and/or squamous cell carcinomas of the facial areas were studied, the macrophages from 2 of these patients possessed cytotoxic macrophages." | 1.27 | The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity. ( Cameron, DJ; Stromberg, BV, 1984) |
| "Mechanisms of bone invasion by squamous carcinomas of the head and neck have been investigated using fresh tumours and established tumour cell lines in an in vitro bone resorption assay with 45Ca-labelled mouse calvaria." | 1.27 | Further observations on mechanisms of bone destruction by squamous carcinomas of the head and neck: the role of host stroma. ( Burman, JF; Carter, RL; Pittam, MR; Tsao, SW, 1983) |
| "Treatment with prednisolone (1." | 1.27 | Association of hypercalcemia with tumors producing colony-stimulating factor(s). ( Asano, S; Kondo, Y; Kosaka, K; Mori, M; Ohkawa, H; Ohsawa, N; Okabe, T; Sato, K; Sato, N; Ueyama, Y, 1983) |
| "Indomethacin seems to inhibit local tumor growth, perhaps through its effects on cellular and humoral immunity and its effects on the host-tissue stroma." | 1.27 | The effect of indomethacin on the growth of epidermoid carcinoma of the palate in rats. ( Blitzer, A; Huang, CC, 1983) |
| "Ten patients with terminal squamous cell carcinoma of the head and neck were treated with indomethacin, and inhibitor of PG synthesis." | 1.27 | Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences. ( Hirsch, B; Johnson, JT; Rabin, BS; Thearle, PB, 1983) |
| "In a prospective study of squamous head and neck cancer, the pretreatment peripheral blood of 125 patients was examined for lymphocyte subclass and in vitro immunologic function." | 1.27 | A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease. ( Brantley, BA; Cole, TB; Crocker, IR; Fisher, SR; Huang, AT; Mold, NG; Wallman, MJ, 1987) |
| "Patients with epidermoid cancer of the head and neck thus have an abnormality of immunoregulatory monocytes that can contribute significantly to their depression of cellular immunity by elaborating prostaglandin E2." | 1.26 | Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. ( Balch, CM; Dougherty, PA; Tilden, AB, 1982) |
| "The treatment of hypercalcemia is directed toward immediate correction of the electrolyte imbalance and long-term control." | 1.26 | Genitourinary malignancy and pseudohyperparathyroidism. ( Barry, JM; Carey, TC; Metcalfe, JB, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (39.73) | 18.7374 |
| 1990's | 26 (35.62) | 18.2507 |
| 2000's | 15 (20.55) | 29.6817 |
| 2010's | 3 (4.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, L | 1 |
| Wu, WK | 1 |
| Li, ZJ | 1 |
| Liu, QC | 1 |
| Li, HT | 1 |
| Wu, YC | 1 |
| Cho, CH | 1 |
| Freeman, SM | 2 |
| Franco, JL | 1 |
| Kenady, DE | 2 |
| Baltzer, L | 2 |
| Roth, Z | 1 |
| Brandwein, HJ | 2 |
| Hadden, JW | 5 |
| Wolf, GT | 1 |
| Fee, WE | 1 |
| Dolan, RW | 1 |
| Moyer, JS | 1 |
| Kaplan, MJ | 1 |
| Spring, PM | 1 |
| Suen, J | 1 |
| Newman, JG | 1 |
| Carroll, WR | 1 |
| Gillespie, MB | 1 |
| Kirkley, TD | 1 |
| Caicedo-Granados, EE | 1 |
| Wuertz, BR | 1 |
| Marker, PH | 1 |
| Lee, GS | 1 |
| Ondrey, FG | 3 |
| Lang, S | 1 |
| Lauffer, L | 1 |
| Clausen, C | 1 |
| Löhr, I | 1 |
| Schmitt, B | 1 |
| Hölzel, D | 1 |
| Wollenberg, B | 1 |
| Gires, O | 1 |
| Kastenbauer, E | 1 |
| Zeidler, R | 1 |
| Yang, CC | 1 |
| Tu, SF | 1 |
| Wu, CH | 1 |
| Chang, RC | 1 |
| Kao, SY | 1 |
| Feinmesser, R | 1 |
| Hardy, B | 1 |
| Sadov, R | 1 |
| Shwartz, A | 1 |
| Chretien, P | 3 |
| Feinmesser, M | 1 |
| Mäkitie, AA | 1 |
| Chau, M | 1 |
| Lim, S | 1 |
| Viani, MA | 1 |
| Gilbert, R | 1 |
| Lim, MS | 1 |
| Jordan, RC | 1 |
| Tímár, J | 2 |
| Forster-Horváth, C | 2 |
| Lukits, J | 2 |
| Döme, B | 2 |
| Ladányi, A | 2 |
| Remenár, E | 2 |
| Kásler, M | 2 |
| Bencsik, M | 1 |
| Répássy, G | 2 |
| Szabó, G | 2 |
| Velich, N | 2 |
| Suba, Z | 2 |
| Elõ, J | 2 |
| Balatoni, Z | 2 |
| Bajtai, A | 1 |
| Talor, E | 2 |
| Pelzmann, M | 1 |
| Thurnher, D | 2 |
| Gedlicka, C | 1 |
| Martinek, H | 1 |
| Knerer, B | 2 |
| Fong, LY | 1 |
| Zhang, L | 1 |
| Jiang, Y | 1 |
| Farber, JL | 1 |
| Roh, JL | 1 |
| Sung, MW | 1 |
| Kim, KH | 1 |
| Godény, M | 1 |
| Bencsik, B | 1 |
| Pócza, K | 1 |
| Zemplén, B | 1 |
| Djalilian, HR | 1 |
| Caicedo, E | 1 |
| Lessan, K | 1 |
| Grami, V | 1 |
| Le, CT | 1 |
| Spellman, SR | 1 |
| Pambuccian, S | 1 |
| Hall, WA | 1 |
| Low, WC | 1 |
| Scheper, MA | 1 |
| Nikitakis, NG | 1 |
| Sauk, JJ | 1 |
| Romeu, J | 1 |
| Chadha, N | 1 |
| Fukilman, O | 1 |
| Dave, P | 1 |
| Lee, M | 1 |
| Balch, CM | 1 |
| Dougherty, PA | 1 |
| Tilden, AB | 1 |
| Mukherjee, PK | 2 |
| Simpson, RW | 2 |
| Cameron, DJ | 1 |
| Stromberg, BV | 1 |
| Tsao, SW | 3 |
| Burman, JF | 3 |
| Carter, RL | 3 |
| Pittam, MR | 1 |
| Kondo, Y | 2 |
| Sato, K | 4 |
| Ohkawa, H | 2 |
| Ueyama, Y | 2 |
| Okabe, T | 2 |
| Sato, N | 1 |
| Asano, S | 1 |
| Mori, M | 1 |
| Ohsawa, N | 2 |
| Kosaka, K | 1 |
| Blitzer, A | 1 |
| Huang, CC | 1 |
| Perkins, TM | 1 |
| Shklar, G | 1 |
| Hirsch, B | 1 |
| Johnson, JT | 2 |
| Rabin, BS | 1 |
| Thearle, PB | 1 |
| Maca, RD | 1 |
| Panje, WR | 3 |
| Easty, DM | 1 |
| Easty, GC | 1 |
| Holmäng, S | 1 |
| Cano, M | 1 |
| Grenabo, L | 1 |
| Hedelin, H | 1 |
| Johansson, SL | 1 |
| Knapp, DW | 1 |
| Chan, TC | 1 |
| Kuczek, T | 1 |
| Reagan, WJ | 1 |
| Park, B | 1 |
| Reeve, VE | 1 |
| Matheson, MJ | 1 |
| Bosnic, M | 1 |
| Boehm-Wilcox, C | 1 |
| Kudriavtsev, IA | 1 |
| Miasishcheva, NV | 1 |
| Snyderman, CH | 1 |
| Klapan, I | 1 |
| Milanovich, M | 1 |
| Heo, DS | 1 |
| Wagner, R | 1 |
| Schwartz, D | 1 |
| Whiteside, TL | 1 |
| Endicott, J | 1 |
| Baekey, P | 1 |
| Skipper, P | 1 |
| Hadden, EM | 1 |
| Stanojević-Bakić, N | 1 |
| Vucković-Dekić, L | 1 |
| Frim, O | 1 |
| Rajner, L | 1 |
| Spuzić, I | 1 |
| Kiriyama, T | 1 |
| Gillespie, MT | 1 |
| Glatz, JA | 1 |
| Fukumoto, S | 1 |
| Moseley, JM | 1 |
| Martin, TJ | 1 |
| Juhn, SK | 3 |
| Adams, GL | 3 |
| Lozano, Y | 1 |
| Taitz, A | 1 |
| Petruzzelli, GJ | 1 |
| Djordjevic, A | 1 |
| Young, MR | 1 |
| Cross, DS | 2 |
| Platt, JL | 2 |
| Bach, FH | 2 |
| Meneses, A | 2 |
| Verastegui, E | 2 |
| Barrera, JL | 2 |
| Zinser, J | 2 |
| de la Garza, J | 2 |
| Alagiakrishnan, K | 1 |
| Botti, AC | 1 |
| Kodali, P | 1 |
| ElAttar, TM | 2 |
| Virji, AS | 1 |
| Michaluart, P | 1 |
| Masferrer, JL | 1 |
| Carothers, AM | 1 |
| Subbaramaiah, K | 1 |
| Zweifel, BS | 1 |
| Koboldt, C | 1 |
| Mestre, JR | 1 |
| Grunberger, D | 1 |
| Sacks, PG | 1 |
| Tanabe, T | 1 |
| Dannenberg, AJ | 1 |
| Bakroeva, M | 1 |
| Formanek, M | 1 |
| Kornfehl, J | 1 |
| Yang, CY | 1 |
| Meng, CL | 1 |
| van der Bijl, P | 1 |
| Lee, HK | 1 |
| Benvenisti, D | 1 |
| Goldberg, H | 1 |
| Metcalfe, JB | 1 |
| Carey, TC | 1 |
| Barry, JM | 1 |
| Pina Boronat, R | 1 |
| Buzón Rueda, JL | 1 |
| Arenas Mirave, JI | 1 |
| Boixeda Miquel, D | 1 |
| Hernández Ranz, F | 1 |
| Moreira Vicente, V | 1 |
| Rodríguez San Pedro, F | 1 |
| Huang, NN | 2 |
| Ahmed, AH | 1 |
| Wang, DJ | 2 |
| Heppel, LA | 2 |
| Kas'ianenko, IV | 1 |
| Pivniuk, VM | 1 |
| Lisitsa, AM | 1 |
| Kovalenko, NA | 1 |
| Bagirian, MA | 1 |
| Rice, SQ | 1 |
| Crane, IJ | 1 |
| Scully, C | 1 |
| Prime, SS | 1 |
| Lapointe, H | 1 |
| Lampe, H | 1 |
| Banerjee, D | 1 |
| Lin, HS | 2 |
| Gonzalez, F | 1 |
| Andrews, J | 1 |
| Halliday, GM | 1 |
| Muller, HK | 1 |
| Tanaka, T | 1 |
| Kojima, T | 1 |
| Yoshimi, N | 1 |
| Sugie, S | 1 |
| Mori, H | 2 |
| Hanabayashi, T | 1 |
| Yamada, Y | 1 |
| Tamaya, T | 1 |
| Nowak, RA | 1 |
| Morrison, NE | 1 |
| Goad, DL | 1 |
| Gaffney, EV | 1 |
| Tashjian, AH | 1 |
| Keukens, F | 1 |
| van Voorst Vader, PC | 1 |
| Panders, AK | 1 |
| Vinks, S | 1 |
| Oosterhuis, JW | 1 |
| Kleijer, WJ | 1 |
| Huang, AT | 1 |
| Mold, NG | 1 |
| Fisher, SR | 1 |
| Brantley, BA | 1 |
| Cole, TB | 1 |
| Wallman, MJ | 1 |
| Crocker, IR | 1 |
| Stiernberg, CM | 1 |
| Rotzler, WH | 1 |
| Valyi-Nagy, K | 1 |
| Hokanson, JA | 1 |
| Hale, PE | 1 |
| el Attar, TM | 1 |
| Rao, AR | 1 |
| Hussain, SP | 1 |
| Fujii, Y | 2 |
| Kasono, K | 1 |
| Tsushima, T | 2 |
| Shizume, K | 2 |
| McCormick, KJ | 1 |
| Mimura, H | 1 |
| Han, DC | 1 |
| Kakiuchi, T | 1 |
| Ono, M | 1 |
| Nomura, H | 1 |
| Perl, A | 1 |
| Láng, I | 1 |
| Gonzalez-Cabello, R | 1 |
| Filep, J | 1 |
| Nékám, K | 1 |
| Gergely, P | 1 |
| Fehér, J | 1 |
| Delaveirre, PH | 1 |
| Hureau, J | 1 |
| Grivaux, M | 1 |
| Chretien, J | 1 |
| Etienne, JP | 1 |
| Thomas, DR | 1 |
| Philpott, GW | 1 |
| Jaffe, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck[NCT00210470] | Phase 2 | 27 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity[NCT02609386] | Phase 2 | 105 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Pilot Study of Immunoregulatory Factor Expression and Immune Responses in Patients With Squamous Cell Carcinoma or Papilloma of the Upper Aerodigestive Tract[NCT00001603] | 93 participants | Observational | 1996-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Immunologic response features were extracted and quantified using a VAS of 0-100 mm to provide for a more continuous variable than the 0-4+ scale that is often used to assess histological responses. The scoring was such that 100 represented the maximum for any sample and 0 represented the lack of any parameter of interest.~See publication of Berinstein, et al., 2012 for complete details." (NCT00210470)
Timeframe: On approximately Day 21 (last day of treatment) prior to undergoing post-treatment surgery
| Intervention | participants with high LI (>34 mm) VAS (Number) |
|---|---|
| IRX-2 Regimen | 18 |
"After participants completed the IRX-2 regimen and the tumor resection was performed, tumor pathology was evaluated from tissue specimens obtained at tumor resection. Formalin-fixed, paraffin-embedded blocks, or unstained slides from the primary tumor were submitted to an independent pathology laboratory for hematoxylin and eosin staining, and evaluation of lymphocyte infiltration (LI). Participants were grouped into a low LI and high LI group based on the change in lymphocyte infiltration from the pretreatment tumor biopsy to the post-treatment tumor surgical resection. 5-year overall survival probabilities were then estimated (Kaplan-Meier) between the low LI and high LI groups" (NCT00210470)
Timeframe: At time of surgery, after treatment with IRX-2 Regimen, assessed up to 5 years
| Intervention | 5-Year OS Probability (Number) |
|---|---|
| High Lymphocyte Infiltration (LI) | 0.80 |
| Low Lymphocyte Infiltration | 0.50 |
Number of participants with the specified percent change in size of target lesion is presented (NCT00210470)
Timeframe: On approximately Day 21 (last day of treatment) prior to undergoing post-treatment surgery
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| -20% to < -10% | -10% to < 0% | 0% to < 10% | 10% to < 20% | 20% to < 30% | >= 30% | |
| IRX-2 Regimen | 4 | 7 | 9 | 1 | 0 | 2 |
Estimate disease-free survival (DFS) (time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy, assessed up to 3 years; margins of resection positive for tumor will not be considered disease recurrence). (NCT00210470)
Timeframe: Time from surgery to death or clinically apparent, biopsy confirmed recurrent or progressive disease after the completion of initial therapy, assessed up to 3 years; margins of resection positive for tumor will not be considered disease recurrence
| Intervention | DFS Probability (Number) | ||
|---|---|---|---|
| 1-year disease free survival probability | 2-year disease free survival probability | 3-year disease free survival probability | |
| IRX-2 Regimen | 0.721 | 0.641 | 0.620 |
To assess measures of immune competence following administration of the IRX-2 regimen, including skin test reactivity. (NCT00210470)
Timeframe: At approx. 21 days, prior to surgery
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Positive at both Baseline and at Day 21 (%) | Negative at both Baseline and Day 21 (%) | Positive at Baseline and Negative Day 21 (%) | Negative at Baseline and Positive at Day 21 | Induration at Day 21 | |
| IRX-2 Regimen | 12 | 6 | 6 | 2 | 3 |
The frequency of all Adverse Events (greater than 5%) is reported. All Serious Adverse Events were described. (NCT00210470)
Timeframe: Enrollment through 30 days post-surgery
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event: Injection Site Pain | Adverse Event: Headache | Adverse Event: Nausea | Adverse Event: Constipation | Adverse Event: Dizziness | Adverse Event: Fatigue | Adverse Event: Pneumonia Aspiration | Adverse Event: Anaemia | Adverse Event: Injection Site Discomfort | Adverse Event: Myalgia | Adverse Event: Contusion | Adverse Event: Dry Mouth | Adverse Event: Vomiting | Additional AE Categories w lower frequency | Serious Adverse Events | |
| IRX-2 Regimen | 6 | 8 | 6 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 4 | 7 |
Estimate overall survival (OS) in patients receiving the IRX-2 regimen. IRX-2 is currently being studied in an on-going Phase 2b clinical trial in patients with newly diagnosed Stage II, III, and IVA squamous cell carcinoma of the oral cavity (INSPIRE) (NCT00210470)
Timeframe: Time from surgery to death or confirmed recurrent or progressive disease, assessed up to 3 years
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| First Year (%) | Second Year (%) | Third Year (%) | |
| IRX-2 Regimen | 92 | 73 | 69 |
Patient Tolerance of Surgery and Post-operative Adjuvant Therapy as measured by median days spent in the hospital, intensive care unit, and step down unit. (NCT00210470)
Timeframe: Following surgery and post-operative therapy (up to 39 days post surgery)
| Intervention | days (Median) | ||
|---|---|---|---|
| Median Days in hospital | Median Days in intensive care unit | Median Days in step-down unit | |
| IRX-2 Regimen | 8.5 | 0.5 | 0.5 |
1 review available for indomethacin and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck: mechanisms of enhancement using prostaglandin synthetase inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; B-Lymphocytes; Carcinoma, Squamous C | 1997 |
7 trials available for indomethacin and Carcinoma, Epidermoid
| Article | Year |
|---|---|
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 2011 |
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F | 2011 |
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F | 2011 |
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F | 2011 |
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-F | 2011 |
Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with multikine.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combinatio | 2003 |
The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in o
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chem | 2003 |
Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma, Squamous Cell; CD4-CD8 Ratio; Cyclophosph | 2005 |
Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery.
Topics: Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Cytokines; Drug Combinatio | 1998 |
Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamid | 2000 |
65 other studies available for indomethacin and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity.
Topics: Adenosine Triphosphatases; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; ATP | 2009 |
The effect of indomethacin on paclitaxel sensitivity and apoptosis in oral squamous carcinoma cells: the role of nuclear factor-κB inhibition.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor | 2011 |
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Cell Movement; Cyclooxyg | 2003 |
In vitro growth inhibition by indomethacin on human oral squamous cell carcinoma lines synergistically suppressed by all-trans retinoic acid correlating to apoptosis.
Topics: Apoptosis; Carcinoma, Squamous Cell; Drug Synergism; Humans; Immunohistochemistry; Indomethacin; Mou | 2002 |
Selective inhibition of cyclooxygenase 2 induces p27kip1 and skp2 in oral squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Surviva | 2003 |
Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cel | 2004 |
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Squamous Ce | 2005 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
Topics: Animals; Cancer Vaccines; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dr | 2007 |
Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Ce | 2007 |
Indomethacin therapy in symptomatic hepatic neoplasms.
Topics: Adenocarcinoma; Aged; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Female; Humans; Indometha | 1982 |
Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients.
Topics: Adult; Aged; Carbazoles; Carcinoma, Squamous Cell; Dinoprostone; Head and Neck Neoplasms; Humans; In | 1982 |
Reversible restriction of vesicular stomatitis virus in permissive cells treated with inhibitors of prostaglandin biosynthesis.
Topics: Animals; Anti-Inflammatory Agents; Carcinoma, Squamous Cell; Cell Line; Cricetinae; Cyclooxygenase I | 1984 |
The ability of macrophages from head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors on cytotoxicity.
Topics: Carcinoma, Squamous Cell; Cell Line; Cytotoxicity, Immunologic; Facial Neoplasms; Female; Head and N | 1984 |
Hypercalcaemia and in vitro osteolysis associated with xenografts of squamous carcinomas of the tongue.
Topics: Animals; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Culture Techniques; Dinoprost; Dinopros | 1983 |
Further observations on mechanisms of bone destruction by squamous carcinomas of the head and neck: the role of host stroma.
Topics: Animals; Bone Resorption; Carcinoma, Squamous Cell; Cell Line; Culture Media; Culture Techniques; Di | 1983 |
Association of hypercalcemia with tumors producing colony-stimulating factor(s).
Topics: Adult; Animals; Calcium; Carcinoma, Squamous Cell; Colony-Stimulating Factors; Female; Granulocytes; | 1983 |
The effect of indomethacin on the growth of epidermoid carcinoma of the palate in rats.
Topics: Animals; Carcinoma, Squamous Cell; Indomethacin; Neoplasm Transplantation; Palatal Neoplasms; Rats; | 1983 |
Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Aspirin; Carcinoma, Squamous Cell; | 1982 |
Immunostimulation of patients with head and neck cancer. In vitro and preliminary clinical experiences.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Immunity, Cellular; Indomethacin; Lymphoc | 1983 |
Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy.
Topics: Carcinoma, Squamous Cell; Concanavalin A; Head and Neck Neoplasms; Humans; Indomethacin; Lymphocyte | 1982 |
Some mechanisms of local bone destruction by squamous carcinomas of the head and neck.
Topics: Adult; Animals; Bone Resorption; Carcinoma, Squamous Cell; Cell Line; Female; Head and Neck Neoplasm | 1981 |
Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor.
Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Head and N | 1981 |
Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced urinary tract carcinogenesis.
Topics: Animals; Body Weight; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cocarcinogenesis; Drug | 1995 |
Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Squamou | 1995 |
The protective effect of indomethacin on photocarcinogenesis in hairless mice.
Topics: Animals; Carcinoma, Squamous Cell; Diet; Erythema; Female; Indomethacin; Mice; Mice, Hairless; Neopl | 1995 |
[Synthesis of arachidonic acid cascade eicosanoids in tumors of various histogenesis in mice].
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Adenocarcinoma; Animals; Arachidonic Acid; Carcinoma, Le | 1995 |
Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck.
Topics: Aged; Aged, 80 and over; Blood; Carcinoma, Squamous Cell; Cell Line; Culture Media; Dinoprostone; Do | 1994 |
Interleukins and contrasuppression induce immune regression of head and neck cancer.
Topics: Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Head and Neck Neoplasm | 1994 |
Enhancement of phytohemagglutinin-induced lymphoproliferative response by indomethacin, Thymex L or their combination in lung cancer patients.
Topics: Adjuvants, Immunologic; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Humans; In | 1993 |
Transforming growth factor beta stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?
Topics: Base Sequence; Carcinoma, Squamous Cell; Culture Media, Conditioned; Gene Expression Regulation, Neo | 1993 |
Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition.
Topics: Arachidonic Acid; Carcinoma, Squamous Cell; Cell Division; Cyclooxygenase Inhibitors; Head and Neck | 1996 |
Prostaglandin E2-protein kinase A signaling and protein phosphatases-1 and -2A regulate human head and neck squamous cell carcinoma motility, adherence, and cytoskeletal organization.
Topics: Actins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Collagen; Cyclic AMP-Dependent Prote | 1996 |
Neoplastic fever: choice of antipyrogenic therapy makes a difference.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Fever; Humans; Indomethacin | 1998 |
Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1999 |
Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.
Topics: Air; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arachidonic Acids; C | 1999 |
Non-steroidal anti-inflammatory drugs inhibit telomerase activity in head and neck squamous carcinoma cell lines.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, | 2001 |
The effect of betel nut extract on cell growth and prostaglandin endoperoxide synthase in human epidermoid carcinoma cells.
Topics: Arachidonic Acid; Areca; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cyclooxygenase Inhibito | 2002 |
Letter: Prostaglandins, indomethacin and hypercalcemia in neoplastic disease.
Topics: Aged; Carcinoma, Squamous Cell; Humans; Hypercalcemia; Indomethacin; Liver Neoplasms; Lung Neoplasms | 1975 |
Genitourinary malignancy and pseudohyperparathyroidism.
Topics: Carcinoma, Squamous Cell; Castration; Dysgerminoma; Female; Furosemide; Humans; Hypercalcemia; Hyper | 1978 |
[Response to the administration of indomethacin in a case of paraneoplastic hypercalcemia].
Topics: Aged; Carcinoma, Squamous Cell; Dexamethasone; Drug Evaluation; Humans; Hypercalcemia; Indomethacin; | 1977 |
Extracellular ATP stimulates increases in Na+/K+ pump activity, intracellular pH and uridine uptake in cultures of mammalian cells.
Topics: 3T3 Cells; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Biological Transport; Carcinoma, | 1992 |
[The immunomodulating role of indomethacin in the chemoradiation treatment of inoperable patients with lung cancer].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 1992 |
Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines.
Topics: Carcinoma, Squamous Cell; Cell Line; Chromatography, Gel; Culture Media; Dose-Response Relationship, | 1992 |
Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Indomethacin; Lymphocytes, Tumor-In | 1992 |
Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Immune Tolerance; Immunity, Cellular; Ind | 1992 |
Effect of retinoids and carotenoids on prostaglandin formation by oral squamous carcinoma cells.
Topics: beta Carotene; Canthaxanthin; Carcinoma, Squamous Cell; Carotenoids; Chromatography, Thin Layer; Fen | 1991 |
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation.
Topics: Adenosine Triphosphate; Aminophylline; Animals; Arachidonic Acids; Aspirin; Carcinoma, Squamous Cell | 1991 |
A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Presenti | 1991 |
Inhibitory effect of the non-steroidal anti-inflammatory drug, indomethacin on the naturally occurring carcinogen, 1-hydroxyanthraquinone in male ACI/N rats.
Topics: Adenocarcinoma; Animals; Anthraquinones; Carcinoma, Squamous Cell; Colonic Neoplasms; Enterocolitis; | 1991 |
Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Squamous Cell; Dinoprostone; Dose-Response Relationship, Immuno | 1990 |
Squamous cell carcinomas often produce more than a single bone resorption-stimulating factor: role of interleukin-1 alpha*.
Topics: Animals; Animals, Newborn; Antibodies; Bone and Bones; Bone Resorption; Carcinoma, Squamous Cell; Ce | 1990 |
Xeroderma pigmentosum: squamous cell carcinoma of the tongue.
Topics: Carcinoma, Squamous Cell; Child; Etretinate; Humans; Indomethacin; Male; Prednisolone; Tongue Neopla | 1989 |
A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Indomethacin; Interleukin-2; Lymphocyte A | 1987 |
Indomethacin inhibits viral RNA and protein synthesis in cells infected with vesicular stomatitis virus.
Topics: Carcinoma, Squamous Cell; Cell Line; Cell Transformation, Viral; Humans; Indomethacin; Laryngeal Neo | 1985 |
Subrenal capsule assay for squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Head and Neck Neoplasms; Humans; Indo | 1986 |
Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Carcinoma, Squamous Cell; Cell | 1987 |
Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin.
Topics: Animals; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Indomethacin; Methylcho | 1988 |
Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the esophagus (EC-GI) derived from a patient with hypercalcemia.
Topics: Aged; Animals; Bone Resorption; Carcinoma, Squamous Cell; Chromatography; DNA; Esophageal Neoplasms; | 1988 |
Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer.
Topics: Adult; Aged; Carbazoles; Carcinoma, Squamous Cell; Dinoprostone; Esterases; Head and Neck Neoplasms; | 1986 |
Production of bone-resorbing activity and colony-stimulating activity in vivo and in vitro by a human squamous cell carcinoma associated with hypercalcemia and leukocytosis.
Topics: Animals; Bone Resorption; Carcinoma, Squamous Cell; Chromatography, Gel; Colony-Stimulating Factors; | 1986 |
Production of interleukin 1 alpha-like factor and colony-stimulating factor by a squamous cell carcinoma of the thyroid (T3M-5) derived from a patient with hypercalcemia and leukocytosis.
Topics: Aged; Bone Resorption; Carcinoma, Squamous Cell; Chromatography, Ion Exchange; Colony-Stimulating Fa | 1987 |
Indomethacin abrogates the suppression by cyclosporin A of lectin-dependent cell-mediated cytotoxicity to HEp-2 cells.
Topics: Carcinoma, Squamous Cell; Cell Line; Concanavalin A; Cyclosporins; Cytotoxicity, Immunologic; Drug A | 1986 |
[Iatrogenic gastroduodenal ulcerations. Corticosteroids excluded].
Topics: Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Duodenal Ulcer; Female; Humans; In | 1973 |
Prostaglandin E (PGE) control of cell proliferation in vitro: characteristics of HT-29.
Topics: Adenocarcinoma; Bucladesine; Carcinoma, Squamous Cell; Cell Count; Cell Division; Cell Line; Culture | 1974 |